HealthDay News — According to a study presented at the annual meeting of the American Society of Clinical Oncology held in Chicago, IL, scientists have developed a new smartphone app that has the potential to help lung cancer patients live longer and better by monitoring their symptoms, while alerting physicians to any potential problems.
Fabrice Denis, MD, PhD, a researcher at the Institut Inter-regional de Cancerologie Jean Bernard in Le Mans, France, and colleagues recruited 133 patients with stage 3 or 4 lung cancer, and randomly assigned them to use either the Moovcare app or undergo standard follow-up. Standard follow-up consisted of a doctor visit and computed tomography (CT) scan every 3 to 6 months, depending on the stage of the patient’s lung cancer. Moovcare patients had the same number of planned doctor visits but underwent planned CT scans only every 6 to 12 months.
Patients used Moovcare once a week to report on 12 clinical symptoms. Their self-reported data was analyzed by an algorithm that triggered an e-mail alert to the patient’s cancer care team if it looked like the risk was high for a relapse or a medical emergency.
The researchers found that 75% of high-risk lung cancer patients were alive 1 year after they started using the Moovcare app, compared with 49% of patients that were provided typical cancer care. Patients also lived 7 months longer, on average, when using Moovcare — about 19 months compared to an average of 12 months for nonusers. Further, Moovcare patients required less regular CT scanning. “The number of imaging scans were reduced by 50% per patient per year,” Denis told HealthDay.
The Israel-based maker of Moovcare, Sivan Innovation, helped fund the trial. The app is still in prototype, but is expected to go on the market in January 2017.
Mobile-Friendly Web Application Extends Lung Cancer Survival [press release]. Chicago, IL: American Society of Clinical Oncology; June 6, 2016.